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Abstract
Background: We evaluated the significance of the genes, defined as DRB1*04 or DRB1*01, in
rheumatoid arthritis (RA) patients. We focused on the role of genetic and serologic markers to
predict disease activity and destructive process of joints.
Methods: Sixty patients with RA were examined. Radiographic changes were evaluated by (Larsen
score) and disease activity was measured by disease activity score 28 (DAS28). The markers
analyzed were: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor
(RF), anti-cyclic citrullinated peptides (anti-CCP2) and HLA-DRB1 alleles typed by PCR.
Results: In this study, anti-CCP antibodies, CRP, RF and AKA were detected in 83.3%, 56.7%,
71.7% and 52% of patients respectively. HLA-DRB1*01 was found in 45% of patients and 35% of
them had one or two HLA-DRB1*04 alleles. According to DRB1*04 subtypes, (DRB1* 0405) was
present in of 80% them. For prediction of grade of activity, the independent predictors were anti-
CCP (OR 19.6), and DRB1*04 positive allele (OR 5.1). The combination of DRB1*04 + anti-CCP
antibodies gave increase in the specificity and positive predictive value to 92% and 90 respectively.
As regards to the prediction of radiological joint damage, the independent predictors were HLA-
DRB1*04, HLA-DRB1*01, RF, and CRP > 18 (OR 5.5, 4.5, 2.5, 2.0 respectively).
Conclusion: Our findings suggest that anti-CCP2 is superior to RF for the detection of RA and
provided predictive information on joint destruction and disease activity. The presence of RA
associated antibodies (ACCP or RF) and/or the SE genes are indicative for a poorer radiological
outcome and higher grade of activity.
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Introduction
Rheumatoid arthritis (RA) is an inflammatory disease of
unknown cause. The course of rheumatoid arthritis is
ranging from mild to aggressive forms, the latter being
very difficult to cope with. It has been shown that early
diagnosis and treatment reduce joint destruction, and
improve survival [1]. Risk factors have been identified in
groups of patients with different outcomes such as base-
line radiographic joint changes, presence of rheumatoid
factor (RF), specific human leukocyte antigens (HLA);
HLA-DRB1 genotypes, high disease activity, high disabil-
ity scores, and high levels of acute phase proteins [2].
Antibodies to cyclic citrullinated peptide (anti-CCP) have
been documented extensively over recent years as highly
specific serological markers for rheumatoid arthritis, with
important clinical implications for diagnosis and progno-
sis [3].
It has been suggested that the etiology of RA is due to an
interaction between genetic and environmental factors.
Genetic studies have demonstrated multiple HLA-DRB1
alleles encoding a conserved sequence at amino acid posi-
tions 70–74 are associated with susceptibility and severity
of RA. This conserved sequence is commonly known as
the shared epitope (SE). The role of the SE in the evolu-
tion of articular destruction has yielded conflicting results
[4,5].
The present study is a cross-sectional analysis aimed to
evaluate the significance of the presence of SE genes,
defined as DRB1*01 or DRB1*04, in relation to anti-CCP
antibodies, antikeratin antibody (AKA) and RF in individ-
uals who developed RA. We focused on disease activity
and joint damage, evaluated on radiographs, as outcome
variables.
Methods
This study was carried out on 60 outpatients who fulfilled
the American college of rheumatology criteria for RA. A
written consent was obtained from the patients according
to the Declaration of Helsinki prior to enrollment in the
study. The study was approved by the Assiut University
local ethical committee. Patients were subsequently
treated with disease modifying antirheumatic drugs (usu-
ally methotrexate, sulphasalazine, or a combination of
both). The patients were evaluated for age; sex; body mass
index; disease duration; duration of morning stiffness;
patients' assessment of pain (on a visual analogue scale);
number of swollen and tender joints, disease activity
score; presence or absence of nodules and extra-articular
manifestations. Disease activity by the disease activity
score (DAS28) [6]. Global health and pain and visual ana-
logue scale were assessed. Functional disability was evalu-
ated using health assessment questionnaire [7]. Hand,
wrist, and foot radiographs were obtained, evaluated and
scored using Larsen method [8].
Sample handling and investigations
Blood samples were collected; for complete blood count,
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP) and DNA isolation. One hundred samples were
taken from healthy blood donors as a control for HLA typ-
ing; twenty of them were used for serologic markers.
Determination of antibodies
RF was detected by the kit supplied Biotec Laboratories
Lot No. RF -460 based on agglutination test using particles
sensitized with human IgG. ANA was detected by the
Fluro-kit supplies by supplied by DiaSorine Catalog No
1740 based on indirect immunoflorescent for the screen-
ing and titration of antinuclear antibodies (ANA). Anti-
CCP2 antibodies were detected by enzyme-linked immu-
nosorbent assay Kit supplies by INOVA Diagnostica Cat.
NO 570139. Serum samples with a test result 25 U/ml
were considered positive, and designated as the "stand-
ard" cut off. AKA was detected by kit supplied by
IMMECO Diagnostic, Lot No. 2120-8, based on indirect
immunofluorescence antibodies on rat esophagus sub-
strate.
HLA-DRB1 genotyping
HLA typing was performed using sequence specific oligo-
nucleotide technique, reversed dot blot hybridization
technique (Dynal RELI HLA-DRB1, product No.802.01)
[9]. DNA for HLA-DRB1 typing of patients was isolated
from peripheral blood mononuclear cells by using the
DNA Isolation Kit (QIAamp minikit, Qiagen, Hilden,
Germany). The biotinylated primers anneal to their target,
Tag DNA polymerase extend the annealed primers along
the target templates to produce a biotinylated DNA
sequence (amplicon). After polymerase chain reaction
amplification, the amplicons are chemically denature-
ated, theses are added to nylon membrane that contains
an array of immobilized sequence specific oligonucle-
otide probes that contain a complementary target
sequence and thus are captured onto the membrane strip.
The amplicon-probe complex is visualized using a colori-
metric reaction. The resulting probe signals are captured
to the control probe intensity and the samples recoded for
interpretation [10]. The specificity of the amplification
can be locus specific (eg, HLA-A, HLA-B, HLA-DRB1)
group specific (eg, DRB1*01, DRB1*02), or allele-specific
(eg,  DRB1-0404,  DRB1-0405). According to HLA-
DRB1*04 subtyping the shared epitopes encoding alleles
*0409,*0413, *0416 and *0421 were classified as *0401
alleles, *0408, *0410 and *0419 were classified as *0404.
The DRB1*0405 alleles were analyzed as a separate entity.
All other DRB1*04  alleles were classified as DRB1*04
non-SE alleles [4].International Archives of Medicine 2008, 1:20 http://www.intarchmed.com/content/1/1/20
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Statistical analysis
Statistical analyses were done using SPSS 15 statistical
software (SPSS Inc, Chicago, Illinois, USA). Continuous
variables were transformed into categorical variables
using the median value as the cut off point. Comparison
of categorical variables between groups, as well as univar-
iate analysis of the relation between all baseline values
and the outcome measure was undertaken using the X2
test, with Fisher's exact correction when appropriate. Sen-
sitivity and specificity, and negative (NPV) and positive
(PPV) predictive values of the possible predictors were cal-
culated. Significant univariate variables were included in
a multivariate stepwise logistic regression model to find
relevant independent prognostic variables. P value < 0.05
is considered significant.
Results
Clinical and laboratory investigations were illustrated in
Table 1. The median age of the patients was 50 years and
90% were women. According the positivity of anti-CCP
antibodies, 50 (83.3%) patients were anti-CCP antibodies
positive. CRP, RF and AKA were detected in 34 (56.7%),
43 (71.7%) and 31 (52%) of patients respectively.
Comparing anti-CCP positive with anti-CCP negative
patients (Table 1); anti-CCP positive patients had a signif-
icantly higher frequency of high ESR, RF, ANA and AKA (P
= 0.04, 0.02, 0.03 and 0.05) respectively.
The frequencies of HLA-DRB1 alleles in patients and con-
trol are shown in Table 2. There was a statistically signifi-
cant increase in the frequency in DRB1*01, DRB1*02,
DRB1*04 compared to control (P = 0.001, 0.05 and 005
respectively). In this study 45% had HLA-DRB1*01 and
35% of patients had one or two HLA-DRB1*04 alleles.
It was found that RF associated allele (DRB1* 0405) was
present in of 80% of DRB1*04 positive patients. "Double
dose" of DRB1*04  (homozygous) was found in 8/60
(13%) of our patients versus 3/100 (3%) in the control P
= 0.05 (Data is not shown in the table).
Predictors of the disease activity grade
Univariate predictors of the grade of disease activity were
summarized in Table 3. Anti-CCP had the highest sensi-
tivity; 97%, and NPV 90%. On multivariate analysis, the
independent predictors of disease activity were anti-CCP
(OR 19.6), and DRB1*04 positive allele (OR 5.1). (Table
Table 1: Clinical and laboratory characteristics of patients
All patients Anti-CCP P value
Negative Positive
Age <50* 45 (75%) 8 (17.8%) 37 (82.2%) NS
≥50 15 (25%) 2 (13.3%) 13 (86.7%)
Sex female 54 (90%) 9 (16.7%) 45 (83.3%) NS
male 6 (10%) 1 (16.7%) 5 (83.3%)
Duration <6m 3 (5%) 1 (33.3%) 2 (66.7%) NS
≥6m 57 (95%) 9 (15.8%) 48 (84.2%)
Smoking yes 5 (8.3%) 1 (20%) 4 (80%) NS
no 55 (91.7%) 9 (16.4%) 46 (83.6%)
CRP <18 * 26 (43.3%) 7 (26.9%) 19 (73.1%) NS
≥18 34 (56.7%) 3 (8.8%) 31 (91.2%)
RF +ve 43 (71.7%) 4 (9.3%) 39 (90.7%) 0.02
6 (35%) 11 (65%)
ESR-1 <32 * 14 (23.3%) 5 (35.7%) 9 (64.3%) 0.04
≥32 46 (76.7%) 5 (10.9%) 41 (89.1%)
ANA +ve 22 (36.7%) 0 (0%) 22 (100%) 0.03
-ve 38 (63.3%) 10 (40.8%) 28 (59.2%)
AKA +ve 31 (52%) 3 (10%) 28 (90%)
-ve 29 (48%) 17 (59%) 12 (41%) 0.05
Grade of activity (DAS)
- Mild or moderete 25 (41.7%) 9 (31.6%) 16 (68.4%) 0.001
- Severe 35 (58.3%) 1 (9.8%) 34 (90.2%)
Larsen score <35* 19 (31.7%) 6 (10%) 13 (21.7%) 0.05
≥35 41(68.3%) 4 (6.7%) 37 (61.7%)
HLA-DRB1*04 +ve 21 (35%) 2 (9.5%) 19 (90.5%) NS
-ve 39 (65%) 8 (20.5%) 31 (79.5%)
HLA-RB1*01 +ve 27 (45%) 5 (19%) 22 (81%) NS
-ve 33 (55%) 5 (15%) 28 (85%)
Values are expressed as n (%). AKA: antikeratin antibody; anti-CCP: anti-cyclic citrullinated peptides antibodies; ANA: antinuclear antibodies; DAS: 
disease activity score; CRP: C-reactive protein; RF: rheumatoid factor; HLA: human leukocyte antigen. * Cut-off values are medians.International Archives of Medicine 2008, 1:20 http://www.intarchmed.com/content/1/1/20
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4) The combination of DRB1*04 + anti-CCP antibodies
gave increase in the specificity and PPV to 92% and 90%,
with a sensitivity and NPV of 42% and 41% respectively.
The presence of single and double gene carriage of the
HLA-DRB1*04 resulted in a significantly higher grade of
disease activity (P = 0.009) compared with its absence.
With regard to a possible gene dosage effect, no statisti-
cally significant difference between double and single
gene carriage of the DRB1*04 was observed (data is not
shown in tables).
Predictors of radiological joint damage
ESR first hour > 32 had the highest sensitivity 98%, and
NPV 93% (Table 5). In multivariate analysis, the inde-
pendent predictors were HLA-DRB1*04, HLA-DRB1*01,
CRP > 18, and RF (Table 6).
Discussion
Anti-CCP-antibody is a synthetic cyclic peptides contain-
ing citrulline. It is incorporated into newly proposed diag-
nostic criteria for rheumatoid arthritis, with higher
sensitivity. The high predictive value of anti-CCP antibod-
ies is indicating that citrullination and production of anti-
CCP antibodies and RF are early processes in the develop-
ment of RA [11]. The present work revealed strong com-
plementarities of RF to anti-CCP as 65% patients lacking
RF found to be positive for anti-CCP. Some reports sug-
gest that RF and anti-CCP should be combined to reach
optimum diagnostic properties [12]. Discrepancy can be
explained by the fact that in the literature stratification for
specificity was not performed, and therefore, the results of
different studies are not comparable [13]. The frequencies
of ANA and AKA were 36%, 52% respectively which indi-
cate that testing for this spectrum of auto antibodies car-
ries little advantage over RF or anti-CCP in diagnosing RA.
A significant association of AKA with Anti-CCP may relate
to that citrulline (profilaggrin) appears to be an essential
Table 2: Frequencies of HLA-DRB1 alleles in patients and 
control
HLA-DRB1 allele Patients Control P value
HLA-DRB1-01 27(45%) 5(5%) 0.001
HLA-DRB1-02 11(18%) 0(0%) 0.05
HLA-DRB1-03 10(16%) 50(50%) 0.03
HLA-DRB1-04* 21(35%) 10(10%) 0.05
- HLA-DRB1-0401 3(15%) 3(13%)
- HLA-DRB1-0404 1(5%) 9(9%)
- HLA-DRB1-0405 17(80%) 77(77%)
DRB1*04 non-SE alleles 0 (0%) 1(1%)
HLA-DRB1-07 4(6%) 25(25%) 0.02
HLA-DRB1-08 6(10%) 5(5%) NS
HLA-DRB-09 1(1.7%) 1(1%) NS
HLA-DRB1-10 0(0%) 15(15%) 0.002
HLA-DRB1-11 5(8.3%) 20(20%) NS
HLA-DRB-12 10(16%) 16(16%) NS
HLA-DRB-13 16(26.7%) 30(30%) NS
HLA-DRB-14 1(1.7%) 4(4%) NS
HLA-DRB1-15 0(0%) 16(16%) 0.002
Values are expressed as n (%). HLA: human leukocyte antigen. 
*According to HLA-DRB1*04 subtyping the shared epitopes encoding 
alleles *0409, *0413, *0416 and *0421 were classified as *0401 
alleles, *0408, *0410 and *0419 were classified as *0404. The 
DRB1*0405 alleles were analyzed as a separate entity. All other 
DRB1*04 alleles were classified as DRB1*04 non-SE alleles.(4)
Table 3: Univariate predictors of disease activity grade
Sensitivity Specificity PPV NPV P value
Anti-CCP present 97% 36% 68% 90% 0.001
RF present 77% 36% 63% 53% NS
CRP > 18 37% 72% 100% 51% 0.002
ESR1 > 32 89% 40% 67% 71% 0.014
ANA 20% 68% 51% 45% NS
AKA 65% 68% 74% 59% 0.01
Age > 50 29% 80% 67% 44% NS
Duration > 6m 97% 8% 60% 67% NS
Smoking 9% 92% 60% 42% NS
Larsen score ≥35 80% 48% 68% 63% 0.02
HLA-DRB1*01 40% 48% 51% 36% NS
HLA-DRB1*04 48% 84% 81% 54% 0.009
AKA: antikeratin antibody; anti-CCP: anti-cyclic citrullinated peptides 
antibodies; ANA: antinuclear antibodies; CRP: C-reactive protein; 
HLA: human leukocyte antigen; NPV: negative predictive value; PPV: 
positive predictive value; RF: rheumatoid factor
Table 4: Multivariate predictors of disease activity grade
OR (95%CI) P value
Anti-CCP present 19.6 (2.1–48.5) 0.009
HLA-DRB1*04 5.1 (1.2–21.1) 0.03
Anti-CCP: anti-cyclic citrullinated peptides antibodies; HLA: human 
leukocyte antigen, OR: Odds ratio; CI: confidence interval.
Table 5: Univariate predictors of radiological joint damage 
(Larsen score)
Sensitivity Specificity PPV NPV P value
Anti-CCP present 90% 32% 74% 60% 0.05
RF present 81% 47% 77% 53% 0.03
CRP > 18 66% 63% 79% 46% 0.05
ESR1 > 32 98% 68% 87% 93% 0.0001
ANA 21% 74% 73% 37% NS
AKA 56% 58% 74% 38% NS
Age > 50 32% 90% 86% 38% NS
Duration > 6m 98% 11% 70% 67% NS
Risk factor 7% 90% 60% 31% NS
HLA-DRB1*01 53% 74% 81% 42% 0.05
HLA-DRB1*04 44% 84% 86% 54% 0.04
AKA: antikeratin antibody; anti-CCP: anti-cyclic citrullinated peptides 
antibodies; ANA: antinuclear antibodies; CRP: C-reactive protein; 
HLA: human leukocyte antigen; NPV: negative predictive value; PPV: 
positive predictive value; RF: rheumatoid factor.International Archives of Medicine 2008, 1:20 http://www.intarchmed.com/content/1/1/20
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constituent of the antigenic determinants recognized by
AKA [14].
In the present work, the sensitivity of anti-CCP was signif-
icantly higher than that of the RFs for prediction of grade
of disease activity. This findings were supported by the
data previously published [1,15].
It was reported that anti-CCP is an important predictor of
radiological outcome. Preventing and diminishing joint
damage is an important treatment goal in early rheuma-
toid arthritis [1].
According the prediction models reported by, Combe et al
[2], for instance, variables reflecting disease activity also
contribute to the prediction of joint damage. In this study,
anti-CCP gave statistically significant differences between
the positive and negative group with radiological damage.
These data are comparable with the findings of other
groups using a similar approach [15-17]. In our study
serum anti-CCP added some prognostic information to
ESR, CRP and RF, and it was the most sensitive predictor
of joint damage, following ESR. These findings were in
agreement with earlier reports [4], but other studies men-
tioned that anti-CCP was the only significant predictor,
together with C reactive protein [18]. Vencovsky et al
reported that the combination RF, CRP and anti-CCP2
antibodies revealed 10 times higher radiological damage
[17] and early erosions [19]. However it was needed to be
emphasized that the results based on dichotomization
not useful in everyday clinical practice. So, we investigated
whether appropriate cut off could be determined to iden-
tify those patients with the most aggressive radiological
course.
Genetic studies have demonstrated that HLA alleles have
been implicated in a number of chronic inflammatory
diseases. RA has been associated with the SE of HLA-
DRB1, which includes DRB1*04  and  DRB1*01  alleles
[19]. In the present study we found a discrepant relation-
ship between RF and anti-CCP2 with the presence of the
SE gene. Also our results do not support the opinion that
there is a direct association between SE gene carriage and
the occurrence of antibodies directed to CCP (or RFs)
leading to the development of RA, but rather suggest that
there is a synergistic interaction between these factors. In
contrast Berglin et al reported that patients with early RA,
had significant association between anti-CCP antibodies
and expression of DRB1*0401/0101 [5]. The conversion
of arginine to citrulline in HLA-DRB1*0401 transgenic
mice has been demonstrated to significantly increase acti-
vation of CD4+ T cells [20], so that individuals carrying
the SE genes may have more sustained T- and B-cell
responses to citrullinated antigens than non carriers [13].
The presence of citrulline within the HLA binding peptide
enhances the peptide-MHC affinity and leads to the acti-
vation of CD4+ T cells during presentation of citrullinated
antigens [20]. This specific T-cell dependent immune
response to citrullinated peptides may contribute to the
occurrence of RA. A quite contradictory suggestion is that
HLA antigens do not predispose to the autoimmune dis-
ease per se but rather fail to provide protection. Abnormal
T-cell regulation associated with certain HLA haplotypes
leads to the loss of self-tolerance followed by polyclonal
activation of T and B cells and the subsequent production
of auto antibodies [21].
In the present work there was a statistically significant dif-
ference observed between carriage of the DRB1*04 and
DRB1*01 alleles with radiological damage and DRB1*04
with disease activity, these findings were in agreement
with those previously reported [13,17]. Recent genome
wide scanning studies using micro satellite loci have con-
firmed that there is strong linkage between this region
with susceptibility and severity of RA [22,23]. Moreover
Petersson et al [4] reported that DRB1*04 SE double gene
dose is associated with disease severity in RA. In contrast
Eberhardt et al [24] did not find the genotypes to be
strongly associated with disease severity after two and five
years.
The role of the SE in the evolution of articular destruction
has yielded conflicting results; however, in most studies
the presence of the SE is associated with increased joint
destruction [14,22]. Others revealed an association
between HLA-DRB1*04 and erosive disease [25], Goronzy
et al [25], and Petersson et al [4] considered homozygos-
ity for HLA-DRB1*04 as a major predictor of the develop-
ment of erosions. In Caucasians of Northern European
origin, the double dose of DRB1*04  SE alleles (0401/
0401 genotype) was associated with radiographic signs of
progressive joint damage [26]. A strong concordance was
revealed between our study and that in East Asian popula-
tions, in which DRB1*0401 is rare and DRB1*0405 is the
most frequent RA associated HLA-DRB1 genotype. The
latter allele has also been reported to be associated with
an increased risk for extra-articular manifestations of RA
[27]. In contrast, others reported that the presence of
shared epitope in single or double dose did not provide
Table 6: Multivariate predictors of radiological joint damage 
(Larsen score)
OR (95%CI) P value
RF present 2.5 (1.1–5.9) 0.01
CRP > 18 2.0 (0.2–5.3) 0.01
HLA-DRB1*01 4.5 (0.4–7.8) 0.002
HLA-DRB1*04 5.5 (0.4–8.7) 0.003
CRP: C-reactive protein; RF: rheumatoid factor; HLA: human 
leukocyte antigen; OR: Odds ratio; CI: confidence interval.International Archives of Medicine 2008, 1:20 http://www.intarchmed.com/content/1/1/20
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any predictive information on the development of joint
damage and was not related to functional outcome [28].
In another study, by Mattey et al [16], reported that a pre-
dictive value of shared epitopes for radiological changes
was restricted to RF negative patients. These discrepancies
may reflect variability in the relative frequencies of HLA-
DRB1*04 in different populations. Possibly, further stud-
ies on larger numbers of patients might solve this issue.
In the Present work the combination between anti-CCP,
and the HLA-DR-B1*04 gave more identification of the
grade of disease activity than a single test alone. The pres-
ence of RF, the SE, and anti-CCP2 antibodies yielded a 10
times higher average expectancy rate for a high radiologi-
cal progression rate compared with the absence of the
three parameters [15,16].
Conclusion
Anti-CCP2 is superior to RF for the detection of RA and
provided predictive information on joint destruction and
disease activity. The presence of RA associated antibodies
and/or the SE genes are indicative for a poorer radiologi-
cal outcome and higher grade of activity. Thus, we shall
need new strategies, both in research and in clinical prac-
tice, where we may now possess a new means for analyz-
ing the risk of RA in individuals who will have different
needs to acquire such information.
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